Valuation: Imunon, Inc.

Market Cap 9.31M 8M 7.5M 6.85M 12.93M 888M 13M 88.81M 34.42M 448M 34.97M 34.22M 1.48B P/E 2026 *
-0.69x
P/E 2027 * -0.89x
Enterprise Value 9.31M 8M 7.5M 6.85M 12.93M 888M 13M 88.81M 34.42M 448M 34.97M 34.22M 1.48B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.86%
Yield 2026 *
-
Yield 2027 * -
1 day-0.97%
1 week+4.04%
Current month+3.39%
1 month+7.44%
3 months-25.28%
6 months-47.98%
Current year-56.85%
1 week 1.52
Extreme 1.52
1.7
1 month 1.47
Extreme 1.47
1.72
Current year 1.47
Extreme 1.47
4.2
1 year 1.47
Extreme 1.47
6.39
3 years 1.47
Extreme 1.47
47.61
5 years 1.47
Extreme 1.47
219.13
10 years 1.47
Extreme 1.47
3,780.03
Manager TitleAgeSince
Chief Executive Officer 56 13/05/2024
Director of Finance/CFO 53 01/07/2026
Chief Tech/Sci/R&D Officer 73 18/02/2025
Director TitleAgeSince
Chairman 75 07/10/2014
Director/Board Member 75 08/07/2011
Director/Board Member 76 15/12/2015
Date Insider Type Main position Quantity % Market Cap.
17/08/26 Sell

General Counsel

-2,449 0.0971%
14/08/26 Free

Chief Technology Officer

3,516 0.1395%
14/08/26 Free

Chief Executive Officer

6,615 0.2624%
Change 5-day change 1-year change 3-year change Capi.($)
-0.97%+4.04%-73.66%-89.84% 9.31M
+3.31%-3.70%+61.03%+103.64% 71.35B
+2.09%+2.28%+49.95%+91.14% 64.17B
-1.60%-0.65%+7.24%-6.88% 28.65B
+0.34%-4.35%-5.44%+478.08% 27.06B
-2.78%+4.47%+52.49%+14.43% 27.33B
-1.68%+0.33%+36.86%-17.91% 20.47B
+1.02%+6.43%+269.42%+420.34% 19.36B
-0.57%-4.06%+10.79%+515.61% 15.96B
-0.05%+4.25%+47.89%+155.64% 14.05B
Average -0.09%+4.52%+45.66%+166.43% 28.84B
Weighted average by Cap. +0.81%+3.31%+55.02%+154.52%

Financials

2026 *2027 *
Net sales - -
Net income -14.47M -12.42M -11.65M -10.64M -20.09M -1.38B -20.19M -138M -53.45M -696M -54.32M -53.14M -2.31B -19.34M -16.6M -15.58M -14.23M -26.86M -1.85B -26.99M -184M -71.47M -931M -72.63M -71.06M -3.08B
Net Debt - -
Logo Imunon, Inc.
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
20
Date Price Change Volume
26/08/26 $1.644 -0.97% 40,990
25/08/26 $1.660 +4.40% 86,616
24/08/26 $1.590 -3.05% 33,053
21/08/26 $1.640 +3.80% 58,859
20/08/26 $1.580 0.00% 123,548
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.660USD
Average target price
17.00USD
Spread / Average Target
+924.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMNN Stock